Reportedly, Johnson & Johnson (JNJ) has submitted its single-shot coronavirus vaccine for emergency use with the Food and Drug Administration for authorization. If authorized, the company plans to supply the U.S. with 100 million doses in the first half of 2021, also it expects to begin shipments immediately after authorization.
Johnson & Johnson’s coronavirus vaccine proved 66% effective at blocking Covid-19 in a Phase 3 study, ahead of FDA’s bar for a minimum of 50% effectiveness. Vaccine stock Pfizer and development partner BioNTech authorized Covid-19 vaccine is 95% effective. Moderna’s is 94.1% effective and is also authorized.
“Today’s submission for emergency use authorization of our investigational single-shot Covid-19 vaccine is a pivotal step toward reducing the burden of disease for people globally and putting an end to the pandemic,” stated J&J’s Chief Scientific Officer Paul Stoffels.
However, J&J claims that its coronavirus vaccine is easier to manufacture and ship and is stable for two years. On the other hand, Moderna says its vaccine can be stored in a standard refrigerator for three months and Pfizer’s vaccine has to be transported and stored at ultra-cold temperatures. Johnson & Johnson informed that it will ship its vaccine using the same cold-chain technologies it already uses.
Dow 30 component Johnson & Johnson (JNJ) is a worldwide healthcare focused company that embraces research and science so that it can provide customers with innovative ideas, products, and services. To learn more about Johnson & Johnson (JNJ) and to continue to track its progress visit the Vista Partners Johnson & Johnson Coverage Page.
If you liked this story please consider, visiting the Atossa Therapeutics (ATOS) dedicated page at Vista Partners to learn about the Seattle-based biotech firm’s work towards finding therapeutic treatments for Breast Cancer and the Coronavirus.
Vista Partners LLC (”Vista”) is a California Registered Investment Advisor based in San Francisco. Vista delivers timely and relevant insights via the website: www.vistapglobal.com with daily stories, weekly market updates, monthly macroeconomic newsletters, podcasts, & Vista’s proprietary equity and market research to help you stay informed and stay competitive. Vista’s mission is to invest partner capital while arming investors with a comprehensive global financial perspective across all market sectors. Vista also seeks to provide select issuers with actionable advice regarding fundamental development, corporate governance, and capital market directives.
Stay Informed! Stay Competitive! Please join us at Vista Partners and receive our FREE email updates throughout the week and view our exclusive content and research.
